FinancialsProfit & Loss
FAQs on Financials of MedGenome
Yes. In FY25, MedGenome reported a profit after tax of ₹46.8 Cr, making it profitable.
MedGenome's revenue grew 36.0% year-on-year, from ₹299.3 Cr in FY24 to ₹407.0 Cr in FY25.
MedGenome's estimated EBITDA for FY25 was ₹81.0 Cr, derived from its profit before tax, finance costs, and depreciation & amortisation.
In FY25, MedGenome posted revenue of ₹407.0 Cr (up 36.0% YoY) and a profit after tax of ₹46.8 Cr. Explore the full financials of MedGenome here...
Disclaimer
Inc42 Datalabs consolidates intelligence from public records, statutory filings, proprietary research, and vetted third‑party datasets. All information is provided as is—please run your own checks before acting on it. Inc42 Datalabs bears no responsibility for decisions or outcomes based on this data.
Quick Links